This poster is published under an
open license. Please read the
disclaimer for further details.
Keywords:
Oncology, Nuclear medicine, PET-CT, Biopsy, Sampling, Tissue characterisation, Neoplasia
Authors:
S. Brocchi, A. Cappelli, C. Mosconi, M. Renzulli, F. Modestino, C. Nanni, T. Balbi, S. Fanti, R. Golfieri; Bologna/IT
DOI:
10.1594/ecr2016/B-1231
Methods and materials
Between November 2014 and September 2015,
10 patients with suspect hypermetabolic findings were enrolled at our institution.
Among them, 8/10 had a suspect malignancy relapse and 2/10 had suspect findings without a previous significant clinical history; 5/10 (50%) had a previous non-diagnostic CT-guided biopsy.
All patients fullfilled the criteria to undergo a real-time FDG PET/CT guided biopsy and had a prior whole body PET/CT scan showing the abnormal focal uptake area.
Five out of ten patients underwent also contrast media injection to depict vessels surrounding the suspect lesion.
After informed consent had been obtained,
real-time biopsies were performed by experienced personnel under direct FDG PET/CT guidance. The needle was tracked by driving its progression into the area with the highest SUVmax through repeated PET/CT acquisition.
A cytological extemporaneous exam was performed during the procedure .